SCHEMBL20337671

SCHEMBL20337671

Cc1ncncc1C(=O)Nc1ccc(Cl)nc1NC1CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.42
FLT3 P36888 2/20 0.39
TYRO3 Q06418 2/20 0.39
MERTK Q12866 2/20 0.39
GAS6 Q14393 2/20 0.39
CRACR2A Q9BSW2 2/20 0.38
ACKR3 P25106 1/20 0.38
IRAK4 Q9NWZ3 4/20 0.37
CYP3A4 P08684 1/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ICOSLG O75144 1/20 0.36
ICOS Q9Y6W8 1/20 0.36
S1PR1 P21453 3/20 0.35
S1PR5 Q9H228 1/20 0.35
MELK Q14680 1/20 0.35
SYK P43405 1/20 0.35
CDK7 P50613 1/20 0.35
CDK9 P50750 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20337645 0.84 XPO1 (0.39) FLT3TYRO3MERTKGAS6IRAK4
SCHEMBL20337657 0.84 IRAK4 (0.39) FLT3TYRO3MERTKGAS6IRAK4
SCHEMBL20345761 0.82 ABL1 (0.41) ABL1CRACR2AACKR3IRAK4ICOSLG
SCHEMBL20345757 0.81 ABL1 (0.42) ABL1CRACR2AACKR3IRAK4CYP3A4
SCHEMBL20337765 0.80 ABL1 (0.43) ABL1CRACR2AACKR3IRAK4ICOSLG
SCHEMBL20337787 0.77 CRACR2A (0.47) ABL1CRACR2AACKR3PDE10A
SCHEMBL20345765 0.76 CRACR2A (0.46) ABL1CRACR2AACKR3IRAK4
SCHEMBL20337682 0.75 CRACR2A (0.47) ABL1CRACR2AACKR3IRAK4PDE10A
SCHEMBL20338377 0.75 ACKR3 (0.38) FLT3TYRO3MERTKGAS6ACKR3
SCHEMBL20337785 0.74 IRAK4 (0.46) ABL1CRACR2AIRAK4PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3562306-B1 METALLOENZYME INHIBITOR COMPOUNDS JI XING PHARMACEUTICALS HONG KONG LTD (HK) 2025-02-26 EP disclosed
US-11919883-B2 Metalloenzyme inhibitor compounds JI XING PHARMACEUTICALS HONG KONG LIMITED (HK) 2024-03-05 US disclosed
US-20220009907-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2022-01-13 US disclosed
US-20220009907-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2022-01-13 US disclosed
US-11136309-B2 Metalloenzyme inhibitor compounds PHASEBIO PHARMACEUTICALS, INC. (US) 2021-10-05 US disclosed
US-11136309-B2 Metalloenzyme inhibitor compounds PHASEBIO PHARMACEUTICALS, INC. (US) 2021-10-05 US disclosed
US-20200392112-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2020-12-17 US disclosed
US-20200392112-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2020-12-17 US disclosed
EP-3562306-A2 METALLOENZYME INHIBITOR COMPOUNDS Selenity Therapeutics (Bermuda), Ltd. (BM) 2019-11-06 EP disclosed
WO-2018125799-A2 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) 2018-07-05 WO disclosed
US-20180186773-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 US disclosed
US-20180186773-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 US disclosed
US-20180186773-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392112-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH ABL1 552/4885FLT3 3774/4885TYRO3 3750/4885
US-20220009907-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH ABL1 552/4885FLT3 3774/4885TYRO3 3750/4885
US-20180186773-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH ABL1 552/4885FLT3 3774/4885TYRO3 3750/4885
US-11136309-B2 Metalloenzyme inhibitor compounds SOD1, RNASE1, FECH ABL1 552/4885FLT3 3774/4885TYRO3 3750/4885
US-11919883-B2 Metalloenzyme inhibitor compounds SOD1, RNASE1, FECH ABL1 552/4885FLT3 3774/4885TYRO3 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.